UNSPSC 51182432: Minodronic acid

This classification denotes a bone resorption inhibitor with the molecular formula C9H12N2O7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40SGR63TGL, chemically known as 1-hydroxy-2-(imidazo(1,2-a)pyridin-3-yl)ethane-1,1-bisphosphonic acid monohydrate but generally known as minodronic acid, which bears US NIH Compound Identifier 130956. European Medicines Agency schedules Minodronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08981MIG.

UNSPSC 51182432 Minodronic acid is a Commodity code for a bisphosphonate pharmaceutical product used to treat bone disorders, primarily osteoporosis and related conditions. State and local governments procure minodronic acid through their health departments, public health agencies, corrections systems, and state Medicaid programs for eligible patient populations — typically inmates, low-income beneficiaries, and other covered populations within their respective systems. The drug is dispensed through state and local pharmacy benefit programs, correctional medical services, and public health clinics rather than purchased as a bulk commodity for general resale.

The source provides no recent state or local contract opportunities tagged to this code. Without posted RFPs, RFQs, IFBs, or ITBs identifying specific issuing bodies, response dates, or procurement activity, no geographic concentration, representative recent solicitations, or issuing-body mix can be characterized. Minodronic acid procurement by state and local agencies appears to occur primarily through standing pharmaceutical supply agreements, state Medicaid managed-care formularies, and corrections medical contracts rather than discrete spot procurements announced in public notice channels.